Synmosa Biopharma (4114) — Cash Flow-to-Debt Ratio
Synmosa Biopharma (4114) has a Cash Flow-to-Debt Ratio of 0.05x as of December 2025, meaning its operating cash flow of NT$185.72 Million could theoretically repay 0% of its total liabilities (NT$3.89 Billion) in one year. See Synmosa Biopharma (4114) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Synmosa Biopharma Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Synmosa Biopharma across 11 annual periods. Also explore 4114 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Synmosa Biopharma (2015–2025)
Year-by-year debt coverage analysis for Synmosa Biopharma. For market capitalisation and broader financial context, see market value of Synmosa Biopharma.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | NT$411.57 Million | NT$3.89 Billion | ▼ -47.0% |
| 2024 | 0.20x | NT$780.62 Million | NT$3.91 Billion | ▲ +41.6% |
| 2023 | 0.14x | NT$511.93 Million | NT$3.63 Billion | ▲ +2.0% |
| 2022 | 0.14x | NT$630.25 Million | NT$4.55 Billion | ▲ +31.5% |
| 2021 | 0.11x | NT$444.29 Million | NT$4.22 Billion | ▲ +83.0% |
| 2020 | 0.06x | NT$254.40 Million | NT$4.42 Billion | ▲ +602.0% |
| 2019 | -0.01x | NT$-44.88 Million | NT$3.92 Billion | ▼ -319.1% |
| 2018 | 0.01x | NT$16.00 Million | NT$3.06 Billion | ▲ +456.2% |
| 2017 | 0.00x | NT$-5.19 Million | NT$3.54 Billion | ▼ -101.5% |
| 2016 | 0.10x | NT$236.48 Million | NT$2.44 Billion | ▲ +549.1% |
| 2015 | 0.01x | NT$23.60 Million | NT$1.58 Billion | — |